Lantheus (NASDAQ:LNTH) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a buy rating in a research report sent to investors on Friday.

A number of other brokerages also recently issued reports on LNTH. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday. Finally, Leerink Partners lifted their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Performance

LNTH traded down $0.81 during mid-day trading on Friday, reaching $87.50. 1,619,155 shares of the stock were exchanged, compared to its average volume of 913,265. The company has a 50 day moving average price of $107.33 and a two-hundred day moving average price of $95.69. The stock has a market capitalization of $6.08 billion, a PE ratio of 14.56 and a beta of 0.51. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $378.73 million during the quarter, compared to analyst estimates of $373.58 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Sell-side analysts expect that Lantheus will post 5.99 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several hedge funds have recently bought and sold shares of LNTH. Moloney Securities Asset Management LLC bought a new position in Lantheus in the 3rd quarter valued at $1,066,000. Hancock Whitney Corp increased its stake in Lantheus by 265.6% in the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock worth $1,254,000 after acquiring an additional 14,639 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the 2nd quarter worth about $290,000. Pitcairn Co. raised its holdings in shares of Lantheus by 117.0% in the 1st quarter. Pitcairn Co. now owns 8,364 shares of the medical equipment provider’s stock valued at $521,000 after acquiring an additional 4,509 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Lantheus during the first quarter worth about $4,151,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.